CLDX News and Press, Celldex Therapeutics Inc. From 06/12/25

Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0) 48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1) KIT related tolerability events demonstrated to be reversible ...

HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company’s Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland. Abstracts will be available on t...

HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said Anthony Marucci, Co-founder, ...

Redwire Corporation (RDW) is expected to report $-0.2 for Q1 2025 Organigram Global Inc. (OGI) is expected to report $-0.03 for Q2 2025 Inter & Co. Inc. (INTR) is expected to report $0.12 for Q1 2025 Pervasip Corp (PVSP) is expected to report for quarter end 2025-02-28 Maui La...

2025-05-08 17:12:46 ET More on Celldex Celldex Therapeutics: Strong Pipeline But Uncertainties Remain Celldex Therapeutics: Will They Get It Right After A Decade Of Failures? Celldex a new overweight at Morgan Stanley on urticaria candidate Seeking Alpha ...

Strong execution and progress across pipeline with multiple key data read outs expected in 2025 Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in June Phase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU under development Pha...

HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence of high numbers of intraepithelia...

National Health Investors Inc. (NHI) is expected to report $1.13 for Q1 2025 Palomar Holdings Inc. (PLMR) is expected to report $1.45 for Q1 2025 Weave Communications Inc. (WEAV) is expected to report $-0.11 for Q1 2025 First National Bank Alaska (FBAK) is expected to report for Q1 20...

2025-05-04 18:48:26 ET Celldex Therapeutics, Inc. (CLDX) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.84%. The average open to low on the day of earnings was -2.38%. The average ope...

2025-05-04 18:43:27 ET Celldex Therapeutics, Inc. (CLDX) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in CLDX stock price following earnings has averaged ±1.18% , with a median of 0.92...